Content Type: Commentary & Opinion

Revisiting FDA Approval of Aducanumab

March 16, 2026

Ensuring Safe Access to Mifepristone During the Pandemic and Beyond

March 16, 2026

Rethinking Global Access to Vaccines

March 16, 2026

A New Way to Contain Unaffordable Medication Costs—Exercising the Government’s Existing Rights

March 16, 2026

Drug Labels: A Flawed Source of Data for Studying Orphan Drug Approvals

March 16, 2026

Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D

March 16, 2026

Coverage of Magnetic Resonance Imaging for Patients with Cardiac Devices: Improving the Coverage with Evidence Development Program

March 16, 2026

Right to Try Requests and Oncologists’ Gatekeeping Obligations

March 16, 2026

Getting the Right Evidence After Drug Approval

March 16, 2026

The Role of Litigation in Defining Drug Risks

March 16, 2026

Balancing Innovation, Access, and Profits—Market Exclusivity for Biologics

March 16, 2026

State Restrictions on Mifepristone Access—The Case for Federal Preemption

March 16, 2026